

**Date:** April 22, 2025

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

Dear Sir/Madam,

**Subject: Update in respect of our intimations dated March 11, 2025 and March 12, 2025, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

With reference to our intimations dated March 11, 2025 and March 12, 2025, regarding acquisition of 8454 equity shares from certain shareholders (Public Category) of Havix Group Inc. D/B/A Aavis Pharmaceuticals (“Havix” or “the Target Company”), we would like to inform that out of the said 8454 equity shares, the acquisition of 7914 equity shares have been completed and acquisition of 540 equity shares is under process due to requirement of certain approvals from Reserve Bank of India (“RBI”).

In view of the above, the time-period for completion of acquisition of the remaining 540 equity shares has been further extended by 60 (sixty) days.

The stakeholders are requested to take note of the same.

Thank you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)  
W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263